Literature DB >> 31415952

Alterations in fibrin formation and fibrinolysis in early onset-preeclampsia: Association with disease severity.

Gordon Haire1, Karl Egan1, Kiran Parmar2, Tom McKinnon2, Cathy Monteith3, Hugh O'Connor3, Barry Kevane4, Patricia Maguire5, Paulina B Szklanna6, Marie Galligan7, Jennifer C Donnelly3, Seamus Allen8, Naomi McCallion3, Beverley Hunt2, Fionnuala Ní Áinle9.   

Abstract

OBJECTIVE: ; Early-onset preeclampsia is a rare pregnancy-specific disorder associated with significantly increased maternal and fetal morbidity and mortality. Whilst it is known that even normotensive pregnancies are associated with changes in clot formation and dissolution, the nature of how these changes differ in those with early onset preeclampsia has not been well established. We sought to evaluate parameters of fibrin formation and fibrinolysis in individuals with early onset preeclampsia in comparison to both pregnant and non-pregnant controls. Furthermore, such parameters were correlated with markers of disease severity in this patient cohort, including the presence of multiorgan involvement, the rate of disease progression and the extent of the anti-angiogenic state in this condition. STUDY
DESIGN: ; Patients with early onset preeclampsia (N = 20) and both pregnant (N = 16) and non -pregnant (N = 16) controls were recruited from the cohort at a large urban maternity hospital which saw over 15,000 deliveries during the study period. Platelet poor plasma was prepared from collected whole blood and analysed for parameters of fibrin formation and fibrinolysis (lagtime to and rate of fibrin formation; PAI-1; PAI-2; D-dimer; plasmin-antiplasmin; tPA) in addition to markers of angiogenesis (sFLT-1; Endoglin) using commercially available specific immunoassays.
RESULTS: ; The maximum rate of fibrin formation as well as PAI-1, PAI-2 and D-dimer levels were all significantly increased in those with early onset preeclampsia and pregnant controls when compared to non-pregnant controls without significant differences between the 2 former groups. Plasmin-antiplasmin levels were significantly reduced in a similar manner. tPA levels were significantly elevated in EOP compared to both pregnant and non-pregnant controls. EOP was associated with significantly increased anti-angiogenic factors (sFLT-1; Endoglin) when compared to both pregnant and non-pregnant controls.
CONCLUSION: ; Markers of fibrin formation and fibrinolysis are significantly alerted in early onset preeclampsia; furthermore, certain markers correlate with disease severity in this patient cohort.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fibrin formation; Fibrinolysis; Preeclampsia; Pregnancy; Severity

Mesh:

Substances:

Year:  2019        PMID: 31415952     DOI: 10.1016/j.ejogrb.2019.07.035

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  4 in total

1.  Alterations of Several Serum Parameters Are Associated with Preeclampsia and May Be Potential Markers for the Assessment of PE Severity.

Authors:  Zhongliang Duan; Cui Li; Wing Ting Leung; Jiangnan Wu; Mingyan Wang; Chunmei Ying; Ling Wang
Journal:  Dis Markers       Date:  2020-01-13       Impact factor: 3.434

2.  The association of antenatal D-dimer and fibrinogen with postpartum hemorrhage and intrauterine growth restriction in preeclampsia.

Authors:  Hailing Shao; Shichu Gao; Dongru Dai; Xiaomin Zhao; Ying Hua; Huijun Yu
Journal:  BMC Pregnancy Childbirth       Date:  2021-09-05       Impact factor: 3.007

3.  Fibrinolytic Changes in Women with Preeclampsia.

Authors:  Anne Cathrine Godtfredsen; Johannes Jakobsen Sidelmann; Britta Blume Dolleris; Jan Stener Jørgensen; Emma Kathrine Jungjohan Johansen; Melissa Fernard Bøg Pedersen; Yaseelan Palarasah; Jørgen Brodersen Gram
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

4.  VTE risk assessment in pregnancy.

Authors:  Karl Ewins; Fionnuala Ní Ainle
Journal:  Res Pract Thromb Haemost       Date:  2019-12-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.